Oral Medicines for the TNF Superfamily and Beyond
PsiThera is developing a pipeline of oral small-molecule programs that target validated immunology pathways. We focus on challenging cytokine systems where biologics dominate the market. PsiThera has advanced tumor necrosis factor (TNF) superfamily programs from novel hits to lead optimization by revealing and stabilizing druggable conformations. We have precisely modulated the protein-protein interactions that are central to immune signaling and built a roadmap for best-in-class therapeutics. By combining physics, AI, structural data, mechanistic biology and experimental validation, PsiThera is positioned to deliver the next generation of oral immunology treatments.